629 related articles for article (PubMed ID: 28205262)
1. Modern multiple myeloma therapy: deep, sustained treatment response and good clinical outcomes.
Landgren O; Iskander K
J Intern Med; 2017 Apr; 281(4):365-382. PubMed ID: 28205262
[TBL] [Abstract][Full Text] [Related]
2. FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy.
Bhatnagar V; Gormley NJ; Luo L; Shen YL; Sridhara R; Subramaniam S; Shen G; Ma L; Shord S; Goldberg KB; Farrell AT; McKee AE; Pazdur R
Oncologist; 2017 Nov; 22(11):1347-1353. PubMed ID: 28904172
[TBL] [Abstract][Full Text] [Related]
3. MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment.
Landgren O; Lu SX; Hultcrantz M
Semin Hematol; 2018 Jan; 55(1):44-50. PubMed ID: 29759154
[TBL] [Abstract][Full Text] [Related]
4. The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies-back to the future!
Kazandjian D; Dew A; Hill E
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101150. PubMed ID: 32139015
[TBL] [Abstract][Full Text] [Related]
5. Current Approach to Managing Patients with Newly Diagnosed High-Risk Multiple Myeloma.
Marneni N; Chakraborty R
Curr Hematol Malig Rep; 2021 Apr; 16(2):148-161. PubMed ID: 33876390
[TBL] [Abstract][Full Text] [Related]
6. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis.
Landgren O; Devlin S; Boulad M; Mailankody S
Bone Marrow Transplant; 2016 Dec; 51(12):1565-1568. PubMed ID: 27595280
[TBL] [Abstract][Full Text] [Related]
7. FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma.
Gormley NJ; Ko CW; Deisseroth A; Nie L; Kaminskas E; Kormanik N; Goldberg KB; Farrell AT; Pazdur R
Clin Cancer Res; 2017 Nov; 23(22):6759-6763. PubMed ID: 28249893
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
Perrot A; Lauwers-Cances V; Corre J; Robillard N; Hulin C; Chretien ML; Dejoie T; Maheo S; Stoppa AM; Pegourie B; Karlin L; Garderet L; Arnulf B; Doyen C; Meuleman N; Royer B; Eveillard JR; Benboubker L; Dib M; Decaux O; Jaccard A; Belhadj K; Brechignac S; Kolb B; Fohrer C; Mohty M; Macro M; Richardson PG; Carlton V; Moorhead M; Willis T; Faham M; Anderson KC; Harousseau JL; Leleu X; Facon T; Moreau P; Attal M; Avet-Loiseau H; Munshi N
Blood; 2018 Dec; 132(23):2456-2464. PubMed ID: 30249784
[TBL] [Abstract][Full Text] [Related]
9. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome.
Roussel M; Lauwers-Cances V; Robillard N; Hulin C; Leleu X; Benboubker L; Marit G; Moreau P; Pegourie B; Caillot D; Fruchart C; Stoppa AM; Gentil C; Wuilleme S; Huynh A; Hebraud B; Corre J; Chretien ML; Facon T; Avet-Loiseau H; Attal M
J Clin Oncol; 2014 Sep; 32(25):2712-7. PubMed ID: 25024076
[TBL] [Abstract][Full Text] [Related]
10. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.
San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG
Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045
[TBL] [Abstract][Full Text] [Related]
11. Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
Xu W; Sun X; Wang B; Guo H
Ann Hematol; 2018 Feb; 97(2):299-307. PubMed ID: 29159498
[TBL] [Abstract][Full Text] [Related]
12. Are maintenance and continuous therapies indicated for every patient with multiple myeloma?
Musto P; Montefusco V
Expert Rev Hematol; 2016 Aug; 9(8):743-51. PubMed ID: 27268855
[TBL] [Abstract][Full Text] [Related]
13. Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.
Palumbo A; Attal M; Roussel M
Clin Cancer Res; 2011 Mar; 17(6):1253-63. PubMed ID: 21411441
[TBL] [Abstract][Full Text] [Related]
14. Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma.
Patel DA; Gopalakrishnan R; Engelhardt BG; McArthur E; Sengsayadeth S; Culos KA; Byrne M; Goodman S; Savani BN; Chinratanalab W; Jagasia M; Mosse CA; Cornell RF; Kassim AA
Bone Marrow Transplant; 2020 Jun; 55(6):1137-1146. PubMed ID: 31992845
[TBL] [Abstract][Full Text] [Related]
15. How I treat first relapse of myeloma.
Harousseau JL; Attal M
Blood; 2017 Aug; 130(8):963-973. PubMed ID: 28679737
[TBL] [Abstract][Full Text] [Related]
16. Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.
Mateos MV; Dimopoulos MA; Cavo M; Suzuki K; Jakubowiak A; Knop S; Doyen C; Lucio P; Nagy Z; Kaplan P; Pour L; Cook M; Grosicki S; Crepaldi A; Liberati AM; Campbell P; Shelekhova T; Yoon SS; Iosava G; Fujisaki T; Garg M; Chiu C; Wang J; Carson R; Crist W; Deraedt W; Nguyen H; Qi M; San-Miguel J;
N Engl J Med; 2018 Feb; 378(6):518-528. PubMed ID: 29231133
[TBL] [Abstract][Full Text] [Related]
17. New Agents in Multiple Myeloma: An Examination of Safety Profiles.
Bringhen S; De Wit E; Dimopoulos MA
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17(7):391-407.e5. PubMed ID: 28601492
[TBL] [Abstract][Full Text] [Related]
18. Maintenance and continuous therapy for multiple myeloma.
Richardson PG; Laubach J; Gandolfi S; Facon T; Weisel K; O'Gorman P
Expert Rev Anticancer Ther; 2018 Aug; 18(8):751-764. PubMed ID: 29932776
[TBL] [Abstract][Full Text] [Related]
19. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Stewart AK; Rajkumar SV; Dimopoulos MA; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel DS; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak AJ; San-Miguel JF; Ludwig H; Wang M; Maisnar V; Minarik J; Bensinger WI; Mateos MV; Ben-Yehuda D; Kukreti V; Zojwalla N; Tonda ME; Yang X; Xing B; Moreau P; Palumbo A;
N Engl J Med; 2015 Jan; 372(2):142-52. PubMed ID: 25482145
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with carfilzomib, lenalidomide and dexamethasone (KRd) results in an unprecedented purity of the stem cell graft in newly diagnosed patients with myeloma.
Tageja N; Korde N; Kazandjian D; Panch S; Manasanch E; Bhutani M; Kwok M; Mailankody S; Yuan C; Stetler-Stevenson M; Leitman SF; Sportes C; Landgren O
Bone Marrow Transplant; 2018 Nov; 53(11):1445-1449. PubMed ID: 29728700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
